Evaluation of anti-pneumococcal capsular antibodies as adjunctive therapy in experimental pneumococcal meningitis. 2006

Christian T Brandt, and Niels Frimodt-Møller, and Jens D Lundgren, and Michael Pedersen, and Ian C Skovsted, and Ian J Rowland, and Christian Østergaard
National Center for Antimicrobials and Infection Control, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark. ctb@ssi.dk

OBJECTIVE Bacteraemia concomitant with meningitis has been shown to greatly affect outcome. Consequently, the efficacy of serotype-specific anti-pneumococcal antiserum (APAS) was investigated in a rat model of pneumococcal meningitis. METHODS Rats were infected with Streptococcus pneumoniae serotype 3. All rats received ceftriaxone starting 26 h post-infection. APAS was administered either at the time of infection or 26 h post-infection and effects were compared with rats treated with antibiotics only. CONCLUSIONS A significant clinical benefit was found when APAS was given at the time of infection whereas no effect was found when administered 26 h after infection. This work indicates that the clinical value of using APAS in pneumococcal meningitis may be limited.

UI MeSH Term Description Entries
D007116 Immunization, Passive Transfer of immunity from immunized to non-immune host by administration of serum antibodies, or transplantation of lymphocytes (ADOPTIVE TRANSFER). Convalescent Plasma Therapy,Immunoglobulin Therapy,Immunotherapy, Passive,Normal Serum Globulin Therapy,Passive Antibody Transfer,Passive Transfer of Immunity,Serotherapy,Passive Immunotherapy,Therapy, Immunoglobulin,Antibody Transfer, Passive,Passive Immunization,Therapy, Convalescent Plasma,Transfer, Passive Antibody
D008586 Meningitis, Pneumococcal An acute purulent infection of the meninges and subarachnoid space caused by Streptococcus pneumoniae, most prevalent in children and adults over the age of 60. This illness may be associated with OTITIS MEDIA; MASTOIDITIS; SINUSITIS; RESPIRATORY TRACT INFECTIONS; sickle cell disease (ANEMIA, SICKLE CELL); skull fractures; and other disorders. Clinical manifestations include FEVER; HEADACHE; neck stiffness; and somnolence followed by SEIZURES; focal neurologic deficits (notably DEAFNESS); and COMA. (From Miller et al., Merritt's Textbook of Neurology, 9th ed, p111) Meningitis, Streptococcus pneumoniae,Experimental Pneumococcal Meningitis,Meningitis, Pneumococcal, Experimental,Meningitis, Pneumococcal, Penicillin-Resistant,Meningitis, Pneumococcal, Recurrent,Experimental Pneumococcal Meningitides,Meningitides, Streptococcus pneumoniae,Meningitis, Experimental Pneumococcal,Pneumococcal Meningitides,Pneumococcal Meningitides, Experimental,Pneumococcal Meningitis,Pneumococcal Meningitis, Experimental,Streptococcus pneumoniae Meningitides,Streptococcus pneumoniae Meningitis
D009043 Motor Activity Body movements of a human or an animal as a behavioral phenomenon. Activities, Motor,Activity, Motor,Motor Activities
D002443 Ceftriaxone A broad-spectrum cephalosporin antibiotic and cefotaxime derivative with a very long half-life and high penetrability to meninges, eyes and inner ears. Benaxona,Cefatriaxone,Cefaxona,Ceftrex,Ceftriaxon,Ceftriaxon Curamed,Ceftriaxon Hexal,Ceftriaxona Andreu,Ceftriaxona LDP Torlan,Ceftriaxone Irex,Ceftriaxone Sodium,Ceftriaxone Sodium, Anhydrous,Ceftriaxone, Disodium Salt,Ceftriaxone, Disodium Salt, Hemiheptahydrate,Lendacin,Longacef,Longaceph,Ro 13-9904,Ro-13-9904,Ro13-9904,Rocefalin,Rocefin,Rocephin,Rocephine,Tacex,Terbac,Anhydrous Ceftriaxone Sodium,Ro 13 9904,Ro 139904,Ro13 9904,Ro139904
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D000907 Antibodies, Bacterial Immunoglobulins produced in a response to BACTERIAL ANTIGENS. Bacterial Antibodies
D013296 Streptococcus pneumoniae A gram-positive organism found in the upper respiratory tract, inflammatory exudates, and various body fluids of normal and/or diseased humans and, rarely, domestic animals. Diplococcus pneumoniae,Pneumococcus

Related Publications

Christian T Brandt, and Niels Frimodt-Møller, and Jens D Lundgren, and Michael Pedersen, and Ian C Skovsted, and Ian J Rowland, and Christian Østergaard
January 2015, Journal of neuroimmunology,
Christian T Brandt, and Niels Frimodt-Møller, and Jens D Lundgren, and Michael Pedersen, and Ian C Skovsted, and Ian J Rowland, and Christian Østergaard
August 2002, European journal of pharmacology,
Christian T Brandt, and Niels Frimodt-Møller, and Jens D Lundgren, and Michael Pedersen, and Ian C Skovsted, and Ian J Rowland, and Christian Østergaard
August 1927, The Journal of experimental medicine,
Christian T Brandt, and Niels Frimodt-Møller, and Jens D Lundgren, and Michael Pedersen, and Ian C Skovsted, and Ian J Rowland, and Christian Østergaard
October 2010, Neurology,
Christian T Brandt, and Niels Frimodt-Møller, and Jens D Lundgren, and Michael Pedersen, and Ian C Skovsted, and Ian J Rowland, and Christian Østergaard
May 1987, The Journal of infectious diseases,
Christian T Brandt, and Niels Frimodt-Møller, and Jens D Lundgren, and Michael Pedersen, and Ian C Skovsted, and Ian J Rowland, and Christian Østergaard
March 1997, Clinical and experimental immunology,
Christian T Brandt, and Niels Frimodt-Møller, and Jens D Lundgren, and Michael Pedersen, and Ian C Skovsted, and Ian J Rowland, and Christian Østergaard
May 2007, Vaccine,
Christian T Brandt, and Niels Frimodt-Møller, and Jens D Lundgren, and Michael Pedersen, and Ian C Skovsted, and Ian J Rowland, and Christian Østergaard
December 2006, Progress in neurobiology,
Christian T Brandt, and Niels Frimodt-Møller, and Jens D Lundgren, and Michael Pedersen, and Ian C Skovsted, and Ian J Rowland, and Christian Østergaard
October 2003, The Journal of antimicrobial chemotherapy,
Christian T Brandt, and Niels Frimodt-Møller, and Jens D Lundgren, and Michael Pedersen, and Ian C Skovsted, and Ian J Rowland, and Christian Østergaard
March 1928, The Journal of experimental medicine,
Copied contents to your clipboard!